TVGN
Tevogen Inc.
Set alert
- YTD
- -64.35%
- 1 year
- -80.37%
- Open
- 5.95
- Prev close
- 6.05
- Mkt cap
- 92.85M
- Vol
- 2.99K
- Avg vol
- 8.53K
- EPS
- -6.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.80
- High
- 6.32
- Forward P/E
- 0.00
- Beta
- -1.03
- Short ratio
- 0.09
- Inst. own
- 3.82%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.49
- 200-d avg
- 1.37
- 1y target
- 4.20
Key statistics
- Market cap
- 176.80M
- Enterprise value
- 235.76M
- Trailing P/E
- 2.89
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.35
- Beta
- -1.03
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 10.55M
- Total cash
- 1.14M
- Total debt
- 2.02M
- Return on equity
- 0.00%
- Shares outstanding
- 175.05M
- Short % of float
- 11.70%
- 50-day average
- 1.49
- 200-day average
- 1.37
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Tevogen Inc.
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tevogen.com
News
- Tevogen Bio (NASDAQ:TVGN) Stock Falls 1.6% – Time to Sell?
- UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
- Tevogen Signs Letter Of Intent To Evaluate A Potential Transaction With HRK Healthcare; Sees Path To Realizing ~$100M In Combined Annual Revenue
- Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
- Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
- Tevogen To Operate Under Tevogen Inc. Name, Effective July 30
- Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
- Tevogen Bio Announces 2026 Annual Meeting of Stockholders
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Tevogen Creates Healthcare Services Initiative Led By VP Of Strategic Initiatives William Keane On Interim Basis
Your note
Sign in to keep a note on TVGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CORBIN CAPITAL PARTNERS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 16, 2023 | 0 |
| DESAI KIRTI | Chief Financial Officer | Purchase | Jun 11, 2024 | 9,699,190 |
| FEIKE JEFFREY L | Director | Stock Award(Grant) | Feb 13, 2024 | 581,771 |
| FLOMENBERG NEAL | Officer | Sale | Oct 16, 2024 | 4,254,300 |
| GOH KEOW LIN | Director | Stock Award(Grant) | Feb 13, 2024 | 193,923 |
| KHAN SADIQ | Officer | Stock Award(Grant) | Feb 13, 2024 | 969,618 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Portland Global Advisors Llc | 1.06% | 1,854,517 | 1.87M | Sep 29, 2024 |
| Polar Asset Management Partners Inc. | 0.90% | 1,577,387 | 1.59M | Sep 29, 2024 |
| Cantor Fitzgerald, L.P. | 0.34% | 603,691 | 609.73K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.20% | 344,285 | 347.73K | Sep 29, 2024 |
| Blackrock Inc. | 0.13% | 230,918 | 233.23K | Sep 29, 2024 |
| HGC Investment Management Inc. | 0.13% | 223,077 | 225.31K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Small Cap Index Fund | 0.12% | 207,166 | 209.24K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.08% | 145,899 | 147.36K | Oct 30, 2024 |
| Vanguard Russell 2000 Index Fund | 0.05% | 88,044 | 88.92K | Aug 30, 2024 |
| iShares Micro Cap ETF | 0.04% | 63,239 | 63.87K | Oct 30, 2024 |
| Schwab Capital Trust-Small Cap Index Fund | 0.03% | 49,581 | 50.08K | Jul 30, 2024 |
| Fidelity Extended Market Index Fund | 0.03% | 57,911 | 58.49K | Oct 30, 2024 |